~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~
~ Additional $100 million available subject to regulatory and financial milestones ~
~ Additional $25 million available subject to Hercules’ approval ~
~ Transaction provides financial flexibility and improves cost of capital ~
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced it entered into a $175 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. The transaction is designed to enhance the company’s financial flexibility to fund the potential commercial launch of AMT-130, its investigational gene therapy for the treatment of Huntington’s disease.
Read More on Fintech : Global Fintech Interview With Justin Meretab, Co‑Founder and CEO of Layer
“This non-dilutive financing keeps funds from the outstanding $50 million debt available until 2030 and provides access to an additional $125 million. We believe this transaction enhances our financial flexibility to fund the potential commercial launch of AMT-130 in the United States, anticipated in 2026,” said Christian Klemt, chief financial officer of uniQure.
The loan facility consists of three tranches, including a first tranche of $50 million refinancing the current debt outstanding at closing and an additional term loan tranche of $100 million, which can be drawn at the company’s option subject to the achievement of both a regulatory milestone related to AMT-130 and a financial milestone. A third tranche of up to $25 million is available, subject to Hercules’ approval. All tranches have a floating interest rate of the greater of 9.45% and the prime rate plus 2.45%, reflecting a current floating rate of 9.70%, compared to the current floating interest rate prior to the refinancing, which would have been 11.95%. The tranches mature in October 2030.
Leerink Partners served as exclusive financial advisor to uniQure on the term loan financing.
Catch more Fintech Insights : The CFO’s New Analyst: Using Generative AI for Strategic Financial Modeling
[To share your insights with us, please write to psen@itechseries.com ]
